Table 1.
Baseline Demographics (n=1006)*
| >/= 65 Years of Age N=460 (%) |
< 65 Years of Age N=546 (%) |
p-value | >/= 70 Years of Age N=270 (%) |
< 70 Years of Age N=736 (%) |
p-value | |
|---|---|---|---|---|---|---|
|
| ||||||
| Sex | ||||||
| Male | 346 (63) | 290 (63) | 0.09 | 178 (66) | 458 (62) | 0.28 |
| Female | 200 (37) | 170 (37) | 92 (34) | 278 (38) | ||
|
| ||||||
| Performance Status | ||||||
| 0 | 156 (34) | 168 (31) | 0.23 | 89 (33) | 235 (32) | 0.65 |
| 1 | 235 (51) | 308 (56) | 140 (52) | 403 (55) | ||
| 2 | 69 (15) | 70 (13) | 41 (15) | 98 (13) | ||
|
| ||||||
| Tumor Histology | ||||||
| Adenocarcinoma | 247 (54) | 330 (61) | 0.20 | 141 (53) | 436 (59) | 0.11 |
| Other | 211 (46) | 215 (39) | 127 (47) | 299 (41) | ||
|
| ||||||
| Cancer Stage | ||||||
| IIIB | 63 (14) | 85 (16) | 0.68 | 41 (16) | 107 (15) | 0.84 |
| IV | 359 (81) | 413 (79) | 208 (80) | 564 (79) | ||
|
| ||||||
| Chemotherapy | ||||||
| carboplatin + gemcitabine | 123 (27) | 167 (31) | 0.4 | 69 (26) | 221 (30) | 0.53 |
| carboplatin + pemetrexed | 76 (17) | 80 (15) | 46 (17) | 110 (15) | ||
| carboplatin + paclitaxel | 138 (30) | 146 (27) | 77 (29) | 207 (28) | ||
| paclitaxel | 123 (27) | 153 (28) | 78 (29) | 198 (27) | ||
|
| ||||||
| Smoking Status | ||||||
| Smoked (current or past) | 373 (92) | 441 (96) | 0.01 | 218 (92) | 596 (95) | 0.15 |
| Never | 34 (8) | 19 (4) | 19 (8) | 34 (5) | ||
*
Percentages may not sum to 100 because of either missing data or rounding.